Hepatitis C Community
HGH, Human Growth Hormone and your Liver
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

HGH, Human Growth Hormone and your Liver

some of you know I've been on HumanGrowthHormone (HGH) for my Pituitary malfunction and Liver repair.
The original thread is posted below.
I thought this study done with HepB patients was very interesting, I don’t usually read things on Heb B…but I’m glad I did in this case. I know it's not the exact same virus, but they are similar in their attacks on the liver…. so notice the difference in how well the HGH group did compared to the control group.
And this was in bad livers.

here's part of the study, for the whole study see the post below:
DISCUSSION
Up to now, there has been no ideal treatment for severe
hepatitis. It was reported that the mortality rate of severe
hepatitis was more than 80% if liver transplantation was
not performed[4]. Liver transplantation is the optimal choice
for treatment of liver failure. Therefore, the fundamental
purpose of internal medical treatment is to make the state
of illness stable and to wait for appropriate liver donor for
liver transplantation[4]. Many complications in severe hepatitis
patients had a close relation to the prognosis[1,2]. It was found
in our previous study that the mortality rate of severe
hepatitis patients with more than two complications was
72.8% and nearly 100% of those with more than four
complications. The pathophysiological mechanism of
multiple organ dysfunction in severe hepatitis patients is
still not clear[1,3]. At present, it is considered that infection
and severe endotoxemia could play an important role
in severe hepatitis with multiple organ dysfunction[1-3].
Malnutrition of severe hepatitis patients, especially chronic
severe hepatitis patients, was the leading cause of accompanying
infections[1,5]. Therefore, if infection is controlled effectively
and endotoxin is removed, malnutrition may improve, and
the multiple organ dysfunction of severe hepatitis patients
may be prevented and cured effectively. According to this
hypothesis, we designed a new therapy method for chronic
severe hepatitis: human GH combined with lactulose enema.
GH, composed of 191 amino acids, is a sort of single
chain polypeptide secreted by adenohypophyseal acidophils.
It is well known that GH not only promote growth and
development but also has comprehensive biological functions,
concerning cell multiplication and differentiation. GH could
also regulate immunity and metabolism[6]. Furthermore, liver
is the main target organ of GH in vivo, and the center of
GH-IGF axis[7,8]. It has been found that decreased serum
IGF-1, IGFBP3 and ALS had a close relation to liver reserve
function and the prognoses of liver cirrhosis patients[9]. It
was also found[10] that serum IGF-1 and IGFBP3 were
decreased in severe viral hepatitis patients while IGFBP1
was increased. The decrease of IGF-1 also had a close
relation to the prognosis of severe hepatitis patients. Assy
et al.[9], performed hypodermic injection in liver cirrhosis
patients with rhGH 0.4 U/kg, and measured serum IGF-1
24 h later with RIA. If IGF-1 <10 nmol/L, the prognosis
was bad, the 1-year survival rate was only 15%; if IGF-1
Table 1 Effects of rhGH on liver function of patients with severe
chronic hepatitis B (mean±SD)
Marker of liver function Pretreatment 2-wk treatment 4-wk treatment
n = 28 n = 28 n = 16
Total protein (g/L) 51.6±4.3 67.8±8.4a 69.2±7.8
Prealbumin (g/L) 80±28 107±54a 108±55
Albumin (g/L) 26.1±4.1 30.2±5.3a 31.9±5.1b
Cholesterol (mg/dL) 76±17 86±32a 96±39
Total bilirubin (mg/dL) 15±14 20±16 12±13
PTA (%) 21.3±5.5 24.7±12.2 36.8±7.9
ALT (IU/L) 117±210 83±77 59±43
AST (IU/L) 171±243 104±79 76±56
aP<0.05, bP<0.01 vs pretreatment.
Table 2 Effects of rhGH on GH-IGF axis in patients with severe
chronic hepatitis B (mean±SD)
Marker of GH-IGF axis Pretreatment (n = 15) 2-wk treatment (n = 15)
GH (ng/mL) 10.4±7.6 6.2±8.1a
IGF-1 (g/mL) 6.3±4.5 8.8±6.7
IGFBP1 (ng/mL) 56.8±47.2 89.7±50.3a
IGFBP3 (g/mL) 3.5±1.7 5.1±3.4
aP10 nmol/L, the 1- and 2-year survival rates of liver
cirrhosis patients were both 100%; indicating that IGF-1
could be used to forecast the prognosis of liver cirrhosis
patients[11,12].

to be continued
Related Discussions
233616_tn?1312790796
..........Our study showed that the GH level of chronic
severe hepatitis patients was high, extraneous human GH
could increase IGFBP1, IGF-1 and IGFBP3, while serum
GH level was decreased. These results indicated that
extraneous GH might improve GH resistance state of chronic
severe hepatitis[10-12]. GH resistance is related to metabolic
disturbances, such as malnutrition, energy metabolism
abnormity, both of which play an important part in
secondary hepatocyte damage and multiple organ dysfunction
of severe hepatitis. On the other hand, the prognoses of
severe hepatitis patients depend on the balance between
necrosis and regeneration of liver. Many cell factors (such
as HGF, HSGF) can stimulate the proliferation of hepatic
cells, but the clinical curative effect is not satisfactory. It
has been found that epidermal growth factor could
significantly alleviate the multiple organ failure due to
thioacetamide. Our study also showed that the use of human
GH for 2-4 wk in treating chronic severe hepatitis patients
could reduce the occurrence and development of
complications, prolong the survival and improve the lifequality
of patients. Serum prealbumin, albumin level
increased and the overall effective rate was 75% without
any obvious side effect[13].
It has been proved that toxic substances (such as
endotoxin, NH3, -GABA, etc.) and high level of inflammatory
cell factors in the serum of severe hepatitis patients could
lead to fever, hypotension, ARDS, and eventually multiple
organ dysfunction[1]. Besides, these substances may affect
the regeneration capacity of liver. Therefore, it is important
to look for an effective method to reduce endotoxin and
inflammatory cell factors. Biological and non-biological
artificial livers could be used to treat severe hepatitis, through
reducing the toxic substances in serum, such as endotoxin
and bilirubin. However, most of the toxic substances could
combine with proteins into large molecules and could not
be filtered through, so treatment should be conducted
repeatedly. Some useful cell factors were also filtered.
Meanwhile there were some complications, such as
secondary bacterial or virus infections. For this reason, the
long-term treatment of severe hepatitis with artificial liver
should be further explored, and at present it has been only used
as the transient therapy before liver transplantation[3].
Professor Fan (Hong Kong University) et al., used selective
filtration to remove toxic substances, and retained some
liver growth factors meanwhile. They achieved perfect
results in animal experiments, but there has been no clinical
experiment[3]. Some scholars utilized tumor necrosis factor
antibody to treat experimental hepatic failure animals, and
also obtained good results, but there is no clinical experiment
report, either.
Lactulose can be decomposed into lactic acid and acetic
acid by enteric bacteria. Both of them can acidify the
intestinal tract, and restrain the production and absorption
of toxic substances, such as endotoxin, NH3, etc., so that
they can remove endotoxin perfectly without severe side
effects. It has been proved by clinical researches that
lactulose can remove endotoxin and decrease the generation
of endotoxin. In this study, we preliminarily observed the
curative effects of human GH associated with lactulose in
treating chronic severe hepatitis, and achieved satisfactory
results. In treatment group, the clinical symptoms of most
of the patients were improved evidently. According to the
modified criteria of therapeutical effect, the markedly
effective rate was 21.4% (6/28), the effective rate was 53.5%
(15/28), the overall effective rate was 75%, and there was
a significant difference compared to the control group. This
result indicated that human GH combined with lactulose could
effectively prevent exacerbation of severe hepatitis, and prevent
and cure its complications. Its mechanisms may lie in the
following factors: preventing the generation and absorption of
intestinal endotoxin, curing endotoxemia; improving GH
resistance of chronic severe hepatitis patients and abnormal
metabolic status, and increasing serum prealbumin, albumin
and cholesterol level. It is preliminarily concluded that
human GH combined with lactulose could prevent and cure
severe hepatitis complicated by multiple organ dysfunction.

Rest of study: http://www.wjgnet.com/1007-9327/11/2981.pdf

Original thread on HGH therapy and the low pituitary function of many HCV patients.

http://www.medhelp.org/posts/show/324670
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis C Community Resources
RSS Expert Activity
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
179856_tn?1333550962
Blank
nygirl7
Planet Earth, CT
476246_tn?1418874514
Blank
Marcia2202
Copenhagen, Denmark
683231_tn?1415953923
Blank
flyinlynn
Auburn, WA
Avatar_m_tn
Blank
can-do-man
IN
317787_tn?1373214989
Blank
Dee1956
DC
Avatar_f_tn
Blank
patra_
DeLand, FL